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Introduction: 
 Endothelial cell (EC) tumors, the most common soft tissue tumors in children, occur in 
1-2% of all children worldwide and present more often in Caucasian child with a rate of up to 
10% (Gordillo & Sen, 2011; Mulliken et al., 2004). Most EC tumors appear on the heads and 
necks of infants, where 50% leave residual deformities even after involution or treatment 
(Biswas et al. 2015). Although the vast majority of EC tumors are classified as benign, such as 
infantile hemangioma, there is still a wide spectrum of malignancy ranging from intermediate-
grade hemangioendotheliomas to aggressive high-grade angiosarcomas (Gordillo & Sen, 2011; 
Wagner et al., 2017).  
 Hemangioendotheliomas (HE), as known as Kaposiform Hemangioendotheliomas 
(KHE), are primarily classified as an intermediate-grade malignancy because of its capacity to 
develop Kasabach-Merritt Phenomenon (KMP). Distinguishing HE tumors from hemangiomas 
are critical for helping prevent KMP, but are sometimes difficult because of their variety of 
clinical morphologies (Fernandez et al., 2009). However, HE tumors occur more frequently on 
the trunk and extremities, appear more purple, and typically do not resolve or disappear on their 
own compared to hemangiomas (Mulliken et al., 2004). Radiological imaging, magnetic 
resonance imaging, or ultrasound may be performed to help identify the types of EC tumor 
(Fernandez et al., 2009). Fortunately, some pharmacologic therapies, such as interferons or high 
dose steroids, can treat both hemangioma and HE. However, HE are typically treated more 
aggressively with chemotherapies, such as vincristine (López et al., 2009). HE tumor resection is 
a definitive treatment. However, HE tumors may cross tissue lines from dermis to subcutis, 
fascia, muscle, and bone making it almost impossible to resect because of the high probability of 
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severe blood loss (Croteau et al., 2013; Blatt et al., 2010). All of these treatments have high-risk 
side effects. Therefore, research needs to focus on understanding the causes of this infantile 
tumor to establish an effective and safe treatment.  
I. Background on Kasabach-Merritt Phenomenon: 
 The first described case of KMP was in 1940 by Haig Kasabach and Katherine Merritt. 
KMP occurs when the HE tumor sequesters blood and platelets, as well as exhibits consumptive 
coagulopathy, which is a marked reduction of platelets with depletion of coagulation factors in 
peripheral blood (Fernandez et al., 2009; Gordillo & Sen, 2011). Without treatment, infants with 
KMP may experience anemia, heart failure, and excessive bleeding, which can all lead to death 
(Gordillo & Sen, 2011). KMP has a mortality rate of up to 30% (Fernandez et al., 2009). 
Fortunately, HE tumors occur without KMP in 29-43% of cases (Ryu et al., 2017). It should also 
be noted that disseminated intravascular coagulopathy (DIC), the activation of clotting cascades, 
is commonly termed as a differential diagnosis for KMP; however, DIC may occur in a variety of 
tumors or malformation, where as KMP forms only in HE tumors (Fernández et al., 2009). Upon 
complete blood count analysis, hemoglobin, hematocrit, and platelet levels should be low to 
determine the diagnosis of KMP, as well as other clinical features associated with consumptive 
coagulopathy.  
 The molecular mechanisms for KMP are not well defined, resulting in less knowledge 
about effective and safe treatments. Possible first-line treatments for HE tumors and KMP are 
corticosteroids, which have variable response rates and approximately one-third of patients do 
not respond to this treatment alone (Ryan et al., 2009; Blatt et. al 2010). A proposed third-line 
treatment is vincristine, which has shown to be a more effective and safer treatment. New 
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findings have discovered that low-dose radiotherapy may also help treat KMP in severe cases 
(Ryan et al., 2009; Yamamoto et al., 2016). Recent studies have proposed a new, more effective 
treatment with Sirolimus, as known as Rapamycin, for KMP (Blatt et al. 2010; Kai et al., 2014). 
However, the noted side effects include mucositis, peripheral edema, hypertension, 
hypertriglyceridemia, hypercholesterolemia, and pneumonitis in rare cases (Blatt et al. 2010). 
Rapamycin treatment is advised to be administered topically because systemic treatments can 
lead to greater side effects (Medici & Olsen, 2012). This treatment is still being tested for its 
effectiveness before it can be provided as a first-line therapy, but evidence has exhibited that it is 
safer than some treatments for KMP (Wang et al., 2015). Overall, rapamycin provides new 
knowledge into the molecular etiologies of KMP.   
II. Molecular Mechanisms Involving Micro-RNA 126 
 HE tumors are described as an angiogenic disease in which abnormal increases in 
capillary vessels result in increased tumor size and trapped platelets to form KMP (Ezekowitz et 
al., 1992). A key angiogenic agent in EC is micro-RNA 126 (miR126), which maintains vascular 
development, regeneration, and integrity as well as promotes angiogenesis (Fish et al., 2008; 
Sinha et al., 2015). Micro-RNAs (miRNAs) are noncoding small RNA molecules (~20-25 nt) 
that have the ability to regulate expression of genes through targeting messenger RNAs (mRNA) 
post-transcriptionally (Fish et al., 2008; Suárez & Sessa, 2009). These molecules can be 
described as an upstream “hub” capable of targeting a variety of downstream sites (Biswas et al., 
2017). miRNAs can bind to the three prime un-translated region (3’UTR) and also the 5’UTR 
region of mRNAs to either repress or activate (less common) translation or degrade the mRNA 
molecule (Wu and Belasco, 2007).  miR126, in particular, has been found to target several 
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coding gene pathways, such as targeting insulin receptor substrate-2 in insulin-secreting β-cells 
and vascular endothelial growth factor-A (VEGF) in gastric cancer, by binding to the 3’UTR of 
the mRNA (Lui et al., 2014; Chen et al., 2014).  
 Studies showed that miR126 mutations in mice result in diminished angiogenesis and 
increased mortality following coronary ligation for myocardial infarction modeling (Wang  
 et al., 2008). Therefore, miR126 is important to vessel formation and mice survivability. miR126 
plays an important role in the upstream activation of VEGF pathway, which is responsible for 
further angiogenic signaling and vessel formation. By repressing negative regulators of the 
VEGF angiogenic pathway, such as Sprouty-related protein (SPRED1) and phosphoinositol-3 
kinase regulatory subunit 2 (PIK3R2/p85-beta), miR126 is a vital aspect of this pathway 
throughout the body (Sinha et al., 2015). Therefore, by applying this concept to HE tumors, 
targeting miR126 processes upstream may provide a new framework for an effective and safe 
treatment.  
III. Role of mammalian Target of Rapamycin (mTOR) and 
Phosphoinositide-3-kinase regulatory subunit 2 (p-85β) in HE 
tumors and KMP 
 As discussed previously, Sirolimus, also known as Rapamycin, is a proposed treatment 
for HE tumors because it targets mammalian Target of Rapamycin (mTOR), a protein that 
activates angiogenesis pathways like VEGF (Wang et al., 2016; Keppler-Noreuil et al., 2016; 
Blatt et al., 2010). Target of Rapamycin (TOR) was first discovered in yeast, Saccharomyces 
cerevisiae, when studying the fungicide rapamycin. Later mammalian studies discovered mTOR, 
which had similar biochemical properties to TOR in yeast and was inhibited by Rapamycin 
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(Pópulo, Lopes, & Soares, 2012). mTOR is a protein serine/threonine kinase that has been shown 
to facilitate EC proliferation (Wang et al., 2017). Structurally, mTOR is constructed for two  
functionally and structurally distinct complexes: mTOR complex 1 (mTORC1) and mTOR 
complex 2 (mTORC2) (Watanabe, Wei, & Hunag, 2011). mTORC1 is the complex responsible 
for positively regulating mTOR kinase activity and rapamycin-sensitivity (Pópulo, Lopes, & 
Soares, 2012). Rapamycin, as an inhibitor of mTOR, decreases angiogenesis through decreasing 
angiogenic responses to VEGF, which inhibits the growth of HE tumors and therefore prevents 
KMP (Keppler-Noreuil et al., 2016; Wang et al., 2017). Hyper-activation of mTOR is found in 
80% of human cancers and Rapamycin is an expected effective treatment (Watanabe et al., 
2011). 
 The cellular processes of mTOR are found in conjuncture with phosphoinositide-3-kinase 
(PI3K) and protein kinase B (AKT) known as the PI3K/AKT/mTOR pathway as seen in Figure 
1 (Keppler-Noreuil et al., 2016). This pathway promotes normal cellular functions such as 
proliferation, growth, cell survival, angiogenesis, and metabolism. Studies have been trying to 
understand the molecular mechanisms behind this pathway to establish treatments for a variety 
of diseases. Many regulatory molecules for this pathway have been identified, such as 
phosphoinositide-3-kinase regulatory subunit 2 (p85β/PIK3R2) and tuberous sclerosis 1 (Tsc1) 
(Mirzaa et al., 2015; Agudo et al., 2014).  PIK3R2 is the gene that encodes for p85β and Tsc1 
encodes for the protein Tsc1. miR126 has been shown to target both of these proteins by binding 
to the 3’UTR of their mRNA, which decreases protein expression (Sessa et al., 2012; Agudo et 
al., 2014). In this current project, p85β, as an inhibitor of mTOR, was analyzed by treatment with 
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miR126 inhibition. Figure 2 demonstrates the proposed interaction between miR126, p85β, and 
mTOR.  
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Figure 2. Proposed mechanism of miR126 relationship with p-85β and mTOR.  Interaction diagram of 
miR126 with the 3 prime untranslated region (3’UTR) of phosphoinositide-3-kinase regulatory subunit 2 (p-85β) 
and the effects on mTOR. Inhibitor of miR126 = miR126i 
Figure 1. PI3K/AKT/mTOR pathway interaction diagram.  Overview of the complex pathway that controls 
proliferation, growth, cell survival, angiogenesis, and metabolism in endothelial cells. Possible inhibitors are 
noted. Diagram taken from: Keppler-Noreuil et al., 2016.
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IV. HE Tumor Model and Treatment 
 For analyzing HE tumor proliferation and KMP mechanisms in vivo, the first established 
and validated endothelial cell line was called hemangioendothelioma endothelial cells (EOMA) 
(Hoak et al., 1971). When injected subcutaneously into 129 P/3 mice, HE tumors arise 
spontaneously with 100% efficiency and effectively model human HE tumors (Gordillo et al., 
2004). These tumors also model KMP found in humans and therefore is the given model for this 
project. After growing the tumor over 3 days, the mice are anesthetized and treated with topical 
tissue nano-transfection (TNT). Simply stated, topical TNT is similar to electroporation for gene 
transfer, however on a much smaller scale, where electric pulses allow the membranes of cells to 
open allowing for molecules to enter the cells (Fei et al., 2013; Gallego-Perez et al., 2017). In 
this project, TNT was used to administer anti-miR126 and anti-control products into the cell to 
study the effects of  miR126 inhibition.  
Aim:  
 The purpose of this project is to test whether miR126 inhibition prevents KMP through 
repression of mTOR. 
Proposed Mechanism:  
 miR126 is an upstream stimulator of mTOR that promotes angiogenesis, which increases 
HE tumor size and susceptibility to KMP. Activation of mTOR is miR126 dependent because 
miR126 inhibits p-85β resulting in mTOR activation. Inhibition of miR126 results in decreased 
mTOR expression by de-repression of p-85β. 
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Methods: 
Cell Culture:  
Mouse hemangioendothelioma endothelial (EOMA) and non-tumor murine aortic endothelial 
cells (MAE) were maintained in Dulbecco's Modified Eagle Medium (DMEM) with 10% Fetal 
Bovine Serum (FBS) and 1% penicillin/streptomycin and incubated at 37˚C and 5% CO2 in T75 
flask or seeded in 12-well plates for further treatment.  
In Vitro Transfection of miRNA: 
EOMA cells taken from T75 plates were seeded in 12-well plates (1 x 105 cells/well) in antibiotic 
free medium for 24 hours at same incubation standards as described above before treatment. 
DharmaFECTTM1 transfection reagent was used to transfect control or miR126 inhibitor 
(Thermo Scientific Dharmacon RNA Technologies). After incubation at 37˚C and 5% CO2 for 72 
hours, cells were washed, lysed, and collect for RNA/protein analysis. 
RNA Extraction and Quantitative Real Time PCR: 
From cell culture, EOMA and MAE cells in T75 plates and EOMA treated in 12-well plates were 
washed with Phosphate Buffered Saline (PBS) and centrifuged into a pellet. RNA was purified 
using miRVana miRNA isolation kit according to manufacturing standards (Ambion/Invitrogen). 
After measuring the RNA concentration, miRNA were reversed transcribed to cDNA by using 
the miR TaqMan assays and TaqMan microRNA reverse transcription kit according to protocol 
(Applied Biosystems/Invitrogen). Abundance of miRNA was quantified by using real-time 
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polymerase chain reaction (PCR) with Universal PCR Master Mix (Applied Biosystems/
Invitrogen).  
Western Blot: 
For immunoblotting, EOMA and MAE cells were lysed, proteins isolated, and concentration 
measured using bicinchoninic acid (BCA) protein assay. 25-40 µg of protein/lane for each 
sample were separated using 4-12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. 
Gel proteins was transferred onto a nitrocellulose membrane and then probed with rabbit 
monoclonal anti-p-85β antibody (1:1000 dilution), anti-(phospho)-mTOR antibody (1:1000 
dilution), and anti-GAPDH antibody (1:5000 dilution). After a series of washing steps with Tris 
Buffered Saline (TBS) and Tris Buffered Saline with Tween 20 (TBST), bands were visualized 
through horseradish peroxidase-conjugated anti-rabbit IgG raised in donkey and horseradish 
peroxidase-conjugated anti-mouse IgG raised in sheep (Amersham Biosciences) at 1:2,000 
dilution and chemiluminescence assay (Amersham Biosciences). Using ImageJ software, 
individual band intensity was measured by pixel densitometry.  
Matrigel® Angiogenesis Assay:  
EOMA cells that were transfected with control inhibitor or miR126 inhibitor were trypsinized 
and resuspended in media at 6 x 104 cells/ml. In a four-well tissue-culture plate, 500µl of cell 
suspension was seeded on growth factor-reduced, phenol red-free Matrigel, according to 
manufacturer’s instruction, and incubated at 37˚C and 5% CO2 overnight. 0.5µl of Calcein AM 
was used to fluorescently stain cell cytoplasms and incubated 37˚C and 5% CO2 for 15 to 60 
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minutes. Zeiss Axiovert 200M microscope was used to capture fluorescent images of tube 
formation. Quantification of tube formation was analyzed using AxioVision LE software version 
3.1 for three images per well to measure total area within the tube under 50X magnification.  
Target Reporter Luciferase Assay: 
MAE cells are trypsinized and seeded in a 12-well plate (0.075 X 106 cells/well) in antibiotic free 
medium for 24 hours before transfection. Then cells were transfected with control mimic and 
miR126 mimic for 72 hours at 37˚C and 5% CO2. Abundance of miR126 was measured from the 
samples using previously described miRNA quantification method. After incubation, cells are re-
transfected with pGL3-p-85β-3-UTR firefly luciferase expression construct (500 ng/sample) 
together with Renilla luciferase pRL-cmv expression construct (10 ng/sample) using 
LipofectamineTMLTXPLUSTMreagent (Invitrogen).  Luciferase activity was determined using 
luciferase reporter assay system. The data are presented as ratio of firefly to Renilla luciferase 
activity. 
In Vivo Studies:  
EOMA cells from T75 flasks were pelleted down from cell culture and washed with PBS. Trypan  
Blue Stain (0.4%) was used to measure cell count. A stock solution of cells in PBS (5 X 106 
cells/100µl) was made and syringes were filled with 100µl for injection. Female 129P/3 mice, 
housed in clean environments in compliance with Institutional Laboratory Animal Care and Use 
Committee guidelines of The Ohio State University, are fed standard chow and water ad libitum. 
Around 6 to 8 weeks of age, dorsal sides of mice are shaved and then further hair removal with 
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Nair. Following this, mice were injected subcutaneously with vehicle EOMA using the prepared 
syringes. After 3 days, mice are treated by tissue nano-transfection with either anti-miR126 and 
anti-control. On the second day after the initial treatment (day 5 after injection), mice are again 
treated by issue nano-transfection with either anti-miR126 and anti-control. Complete blood 
counts taken from OSU Comparative Pathology and Mouse Phenotyping Core for days 0, 5, and 
10. Hemoglobin, hematocrit, and platelet levels for each day were plotted on a box and whisker 
plot to compare control and treatment.  Figure 3 provides a timeline of in vivo treatment. 
Statistical Analysis:  
All experiment were conducted at least twice. Two-sided two-sample t-tests were used to 
compare differences between two groups unless otherwise stated. All bar graphs represent means 
with error bars of one standard deviation. p-value of <0.05 is consider statistically significant.  
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Figure 3. Targeted Inhibition of miR126 in HE Tumors. 129P/3 mice injected with EOMA cells. After 3 days 
are treated with anti-miR126 and anti-control through tissue nano-transfection (TNT). TNT is similar to 
electroporation for gene transfers. Complete blood counts were taken on day 0, 5, and 10.
3 days
Treatment (twice a week: d3 
and d5) with anti-miR126 or 
anti-con by TNT
d5d0 d3
blood 
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Results:  
  
 To determine miR126 abundance in EOMA cells, real-time PCR was performed 
comparing EOMA and MAE cells. EOMA cells have a significantly higher abundance of  
miR126 compared to MAE cells (Fig. 4-A). After transfection with miR126 inhibitor and control 
inhibitor in EOMA cells, miR126 levels significantly decrease in the miR126 inhibitor group, as 
expected (Fig. 4-B). To examine functionality of miR126 inhibition, Matrigel® assay was 
performed to test tube formation. Following transfection with with miR126 inhibitor and control 
inhibitor in EOMA cells, there was a significant decrease EOMA cell tube forming capacity with 
treatment of miR126 inhibitor compared to control inhibitor (Fig. 4-C and 4-D). Inhibition of 
miR126 results in decreased angiogenesis in EOMA cells. Therefore, miR126 angiogenic factors 
are necessary for HE growth.  
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Figure 4. miR126 elevated in EOMA cells 
promotes angiogenesis necessary for HE 
growth. (A) qPCR shows high relative 
abundance of miR126 in EOMA compared to 
MAE. (B) qPCR results show effective 
knockdown of miR126 by treating EOMA 
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formation by luminal area show significant 
decrease in formation when treated with 126i 
compare to con inh. (n=6 per group, *p<0.05)
EOMA
MAE
A. B.
C. D.
Clark
 Having identified increased abundance of miR126 in EOMA cells, the next step was to 
determine if miR126 targeted p-85β. This was tested by construction of a firefly luciferase 
reporter plasmid with the p-85β 3’UTR sequence. p-85β reporter plasmid was co-transfection 
with Renilla firefly luciferase reporter plasmids into MAE cells previously treated with miR126 
mimic and control mimic. MAE cells were used instead of EOMA cells to control for the 
miR126 abundance. As expected, MAE cells treated with miR126 mimic had a higher abundance 
of miR126 compared to control mimc (Fig. 5-A). Following co-transfection, there was a 
significant decrease in luciferase levels in the MAE cells treated with miR126 mimic compared 
to control mimic (Fig. 5-B). This confirms that miR126 targets the 3’UTR of p-85β as diagramed 
in Figure 2.  
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 After determining that miR126 directly inhibits p-85β, identifying that p-85β and mTOR 
were miR126 dependent was the final in vitro procedure to verify. Expression of p-85β and 
mTOR were first analyzed in both EOMA and MAE cells to understand the inverse relationship 
between mTOR and p-85β. Immunoblot in Figure 6-A shows significantly lower expression of 
p-85β in EOMA cells compared to MAE cells. Phosphorylated mTOR (p-mTOR), the active 
form of mTOR, was blotted to show significant increase in mTOR expression in EOMA cells 
compared to MAE cells (Fig. 6-B). EOMA cells were then transfected with miR126 inhibitor and 
control inhibitor to examine the effects on p-85β and mTOR expression. Figure 6-C and 6-D 
confirmed that with inhibition of miR126, expression of p-85β increases significantly and mTOR 
decreases significantly. This data supports the proposed mechanism of this work that p-85β and 
mTOR are miR126 dependent. As miR126 levels decreases, mTOR expression decrease because 
p-85β is de-repressed and targets mTOR. 
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 The last experiment was to analyze miR126 inhibition in vivo, since it was found 
previously that inhibition of mTOR results in decrease HE growth and susceptibility to KMP in 
humans. 129P/3 mice were inject subcutaneously with EOMA cells and treated with tissue nano-
transfection with anti-miR126 (n=5) or anti-control (n=4) on days 3 and 5. Complete blood 
counts was taken on days 0, 5, and 10 for hematocrit, hemoglobin, and platelets. In addition, 
blood smears were performed to identify reticulocytes. Box plots for hematocrit (Fig. 7-A), 
hemoglobin (Fig. 7-B), and platelets (Fig. 7-C) were created to show the medians, ranges, upper 
and lower quartiles, and positive and negative standard deviations. No statistical significance can 
be drawn from this preliminary data. There is a slight decreasing trend in the platelets of the anti-
control treated group compared to the anti-miR126. Reticulocytes were seen in the blood smear 
of one anti-control treated animal (control 4) and not in anti-miR126 treated mice. This indicates 
possible hemolytic anemia and/or fragmented cells due to disseminated intravascular coagulation 
within this mouse, which is consistent with consumptive coagulopathy in KMP.  
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Discussion:  
 KMP in HE tumors is associated with significant morbidity and a mortality rate of up to 
30% (Ryan et al., 2009). Fortunately, the incidence of KMP is low, where only < 1% of all 
children with vascular tumors are affected and 29-43% of HE tumor cases occur without KMP 
(Ryu et al., 2017). HE tumors with KMP utilize different cellular mechanisms to promote tumor 
growth through increased angiogenesis by activation of PI3K/AKT/mTOR and VEGF pathways 
(Keppler-Noreuil et al., 2016). Rapamycin, an inhibitor of mTOR, has been found to be an 
effective treatment for KMP and provided insight into its development. As the molecular 
etiologies for KMP are still not well studied, this project focused on deciphering some of its 
mechanisms.  
 Recently, a variety of miRNAs have revealed as biomarkers for many different molecular 
mechanisms and provided evidence as potential therapeutic targets for tumor management 
(Gordillo et al., 2014). To study the effects of miRNAs, EOMA cells, a validated model for HE 
tumors, were used. miR126, which has been found in abundance in several other tumor cells, 
was also found to have a significantly high abundance in EOMA cells compared to MAE cells 
(Fig. 4-A) (Ebrahimi et al., 2013). After miR126 inhibition, EOMA cells decreased in its ability  
to form tubes for angiogenesis (Fig. 4-C and 4-D). Vessel formation is key aspect for HE tumor 
growth and susceptibility to KMP. Therefore, regulating the vasculature process by inhibiting 
miR126 may provide useful for treating HE tumors.  
 For further examination on the role of miR126 in regulating angiogenesis, 3’UTR 
luciferase assays were performed on MAE cells with control and miR126 mimic to test miR126 
binding to the mRNA of p-85β. In previous studies, miR126 has been shown to inhibit EC 
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expression of p-85β, a known negative regulator of mTOR (Sessa et al., 2012). In this project, 
miR126 was shown to target the 3’UTR of p-85β and significantly decrease its expression level 
(Fig. 5-B). This finding provides evidence that miR126 is important for mTOR activation, since 
miR126 inhibits p-85β, a mTOR repressor.   
 Immunoblots showed that p-85β expression is significantly lower in EOMA cells 
compared to MAE cells and mTOR expression is significantly higher (Fig. 6-A and 6-B, 
respectively). Following treatment with miR126 inhibitor and control inhibitor in EOMA cells, 
p-85β expression levels significantly increased and mTOR expression levels significantly 
decrease with miR126 inhibition compared to control inhibitor (Fig. 6-C and 6-D, respectively). 
mTOR and p-85β expression are miR126 dependent. As p-85β decreases mTOR expression, 
vessel formation will decrease through decreasing angiogenic responses to VEGF, which inhibits 
the growth of HE tumors and therefore prevents KMP.  
 Effects of miR126 inhibition was tested in vivo.  As discussed previously, EOMA cells 
injected subcutaneously into 129P/3 mice spontaneously form HE tumors and all develop KMP 
without treatment. Following tumor formation, topical TNT with anti-miR126 and anti-control 
was used to study impact of miR126 inhibition. Complete blood counts (CBCs) taken throughout 
experiment (described in Figure 3) and plotted on box plots to compare the levels of hematocrit, 
hemoglobin, and platelet. KMP is characterized by low hematocrit, hemoglobin, and platelet 
levels as well as reticulocytes on blood smear analysis. Data does not show significance in 
decreased of hematocrit, hemoglobin, and platelet levels in the anti-control compared to anti-
miR126 (Fig. 7-A through 7-C). There is a slight trend in decreasing platelet levels in anti-
!20
Clark
control verse anti-miR126 groups. On one anti-control blood smear, there was identification of 
reticulocytes, which was not seen in anti-miR126 group.  
 There are no significant findings that provide evidence that KMP was prevented by 
inhibition of miR126. Several components may have affected the intended results. The 
experiment should have studied the mice until death with more time points for CBC and a 
survival analysis using a Kaplan-Meier curve could have been performed. To generate a greater 
statistical significant power, a larger sample size could have been used, which would have 
narrowed the range for standard error. This was also the first experiment to administer anti-
miR126 into HE tumors through topical TNT. We are currently working on more in vivo 
experiments to resolve these challenges.   
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Future Directions:  
  
 MicroRNAs have been gaining more recognition for their molecular mechanisms, effects 
on vital cellular pathways, and applications as therapeutic targets. Two approaches to miRNA-
based therapeutics have been tested. The first is developing miRNA silencers that are able to 
inhibit the production of miRNAs (Voglova, Bezakova, & Herichova, 2016). This has been 
shown to be effective in clinical trials for blocking liver-expressed miR122 in hepatitis C 
infections. The second approach is centered around miRNA replacement therapy, or miRNA 
mimics, to restore lost physiological function or lower abundance of miRNAs. This approach is 
still in clinical cancer trials focused around up-regulating miRNAs that function as tumor 
suppressors (Voglova, Bezakova, & Herichova, 2016).  
 After further murine studies that will hopefully discover miR126 importance in HE 
tumors and KMP, this miRNA could be used as a therapeutic target for treatment. In particular, as 
Voglova et al. described, development of a miR126 silencer that could be administered 
intravenously, orally, or topically. However, this method may have other serious side effects 
because miR126 is important in many pathway throughout the body, other than inhibiting p-85β 
to activate mTOR upstream.  
 Another method for targeting miR126 is the use of TNT in a clinical setting. Gallego-
Perez et al. proposes that topical TNT may be administered all at one-time with a short treatment 
period, lasting only seconds. The anti-miR126 could be administered once into human HE 
tumors for effective, safe, directed treatment. This treatment could also be used in conjunction 
with current HE tumor treatments, such as corticosteriods, rapamycin, or vincristine (Ryan et al., 
2009; Blatt et. al 2010).   
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 Following this project, the most immediate direction to take is to determine the 
significant role of miR126 inhibition in vivo. As the first project to identify that mTOR and 
p-85β expression are dependent on miR126 abundance in HE tumors, there will need to be more 
studies to further analyze this relationship and related relationships. This project has provided 
more insight into the etiologies and treatments for KMP. With this new knowledge, this project 
has taken steps towards discovering a more effective and safer treatment for KMP to overall 
decrease the incidence of death due to this phenomenon. 
!23
Clark
Conclusion:  
 HE tumors are a type of EC tumors that have intermediate-grade malignancy because of 
their susceptibility to develop KMP, characterized by consumptive coagulopathy. Although KMP 
is rare, the mortality rate is up to 30% in infants that are diagnosed and most of these tumors do 
not resolve on their own, which presents a serious threat to the infant’s well-being. This project 
was the first to identify that mTOR and p-85β expression are dependent on miR126 abundance in 
HE tumors that develop KMP. Inhibition of miR126 results in decreased mTOR expression by 
de-repression of p-85β, a negative regulator of mTOR. Further murine studies are being 
performed to establish how inhibition of miR126 may prevent KMP. After significantly 
identifying this relationship, miR126 may be used as a therapeutic target for HE tumor treatment 
with the goal of preventing further infant deaths from KMP.  
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